Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated ...

Background: Non-alcoholic-steatohepatitis (NASH) leading to fibrosis, end-stage cirrhosis and hepatocellular carcinoma is an increasing health problem in the Western world. Thus, the need for new ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1241 in Combination with Efruxifermin Shows Enhanced ...

This theory is supported by the observations that animals fed a high-fructose diet develop hepatic steatosis and exacerbation of diet-induced NASH. [56–58] Recently, Ouyang et al. correlated ...

Excess free fatty acids, an imbalance of adipocytokines and mitochondrial dysfunction all contribute to abnormalities in hepatocellular lipid content in diabetes and can lead to steatosis and ...

Agbaje found that adjusted WHtR high fat mass predicted liver steatosis (odds ratio [OR], 1.63) and fibrosis (OR, 1.31). Similarly, excess WHtR fat mass was associated with liver steatosis (OR, 4.02) ...

Agbaje found that adjusted WHtR high fat mass predicted liver steatosis (odds ratio [OR], 1.63) and fibrosis (OR, 1.31). Similarly, excess WHtR fat mass was associated with liver steatosis (OR, 4. ...

Inflammation: Driving Force of NASH Previous single-point cross-sectional studies have identified components of the metabolic syndrome to be associated with NASH and fibrosis. [33–39] These ...

It's thought that failure to return to this balance may result in persistent inflammation and fibrosis because of uncontrolled IL-22 activity, delaying tissue recovery.

(28:54) 3 Episode 3 - Episode 3: Approaching the Treatment of NASH Holistically With Multispecialty Collaboration and Patient Education (17:01) By Clinical Content Hub × ...

MASH has become the leading cause of liver disease worldwide, and the prevalence of MASH is steadily increasing. The development of new drugs for the treatment of MASH is urgent. Silybin has been used ...